1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: developing antimicrobial drugs-general considerations for clinical trials. Draft guidance. July 1998. Available at: http://www.fda.gov/cder/guidance/2580dft.pdf. Accessed 28 January 2008.
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antibacterial drug products: use of noninferiority studies to support approval. Draft guidance. October 2007. Available at: http://www.fda.gov/cder/guidance/7884dft.pdf. Accessed 28 January 2008.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: choice of control group and related issues in clinical trials: E10. Recommended for adoption at step 4 of the ICH process on 20 July 2000 by the ICH Steering Committee. Available at: http://www.bcg-usa.com/regulatory/docs/ich/ICHE10.pdf. Accessed 28 January 2008.
4. Bayer. BAY12-8039: 5 days sinusitis vs placebo. Trial identifier NCT00492024. Available at: http://clinicaltrials.gov/ct2/show/NCT00492024?term=NCT00492024&rank=1. Accessed 2 June 2008.